Avalyn Pharma (NASDAQ:AVLN) Insider Fmr Llc Sells 175,000 Shares of Company Stock

Avalyn Pharma Inc. (NASDAQ:AVLN) insider Fmr Llc sold 175,000 shares of Avalyn Pharma stock in a transaction that occurred on Monday, November 9th. The shares were sold at an average price of $29.07, for a total value of $5,087,250.00. Following the sale, the insider directly owned 2,109,535 shares in the company, valued at $61,324,182.45. The trade was a 7.66% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

Fmr Llc also recently made the following trade(s):

• On Tuesday, November 10th, Fmr Llc sold 53,454 shares of Avalyn Pharma stock. The shares were sold at an average price of $30.21, for a total value of $1,614,845.34.

Avalyn Pharma Price Performance

Avalyn Pharma stock opened at $30.59 on Friday. The stock’s 50 day moving average is $28.77. The company has a debt-to-equity ratio of 0.04, a current ratio of 33.12 and a quick ratio of 33.12. The company has a market cap of $1.36 billion and a P/E ratio of -1.34. Avalyn Pharma Inc. has a one year low of $22.24 and a one year high of $40.17.

Avalyn Pharma (NASDAQ:AVLN) last released its quarterly earnings results on Thursday, November 12th. The company reported ($0.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.03). Equities analysts anticipate that Avalyn Pharma Inc. will post -3.86 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on AVLN. Morgan Stanley boosted their price target on shares of Avalyn Pharma from $53.00 to $57.00 and gave the stock an “overweight” rating in a research note on Thursday, August 13th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Avalyn Pharma in a report on Wednesday. Wall Street Zen downgraded shares of Avalyn Pharma from a “hold” rating to a “sell” rating in a research report on Sunday, September 20th. Finally, Raymond James Financial began coverage on shares of Avalyn Pharma in a report on Friday, October 2nd. They set an “outperform” rating and a $60.00 price objective on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $60.00.

Institutional Investors Weigh In On Avalyn Pharma

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Montanova Capital LLC bought a new stake in Avalyn Pharma in the 2nd quarter valued at approximately $82,402,000. Braidwell LP bought a new position in shares of Avalyn Pharma during the 2nd quarter worth approximately $26,382,000. State Street Corp raised its holdings in shares of Avalyn Pharma by 73.7% in the third quarter. State Street Corp now owns 554,004 shares of the company’s stock valued at $15,784,000 after purchasing an additional 235,009 shares during the last quarter. Bank of New York Mellon Corp acquired a new stake in shares of Avalyn Pharma in the second quarter valued at approximately $1,321,000. Finally, Profund Advisors LLC bought a new stake in shares of Avalyn Pharma in the third quarter worth $668,000.

About Avalyn Pharma

Avalyn Pharma is a clinical-stage biopharmaceutical company developing inhaled treatments for pulmonary fibrosis, including idiopathic pulmonary fibrosis and other progressive fibrotic lung diseases. Its approach is designed to deliver medicine directly to the lungs. The company’s pipeline includes AP01, an investigational inhaled formulation of pirfenidone, and AP02, an investigational inhaled formulation of nintedanib. Both medicines are based on drugs used in oral form for pulmonary fibrosis, but Avalyn’s inhaled candidates are being studied as potential alternatives to oral treatment.